Home / Market News / $BMRN
fiscal.ai Corporate Catalyst Impact 55/100 ● negative

Wedbush Trims Price Target on BioMarin Pharmaceutical to $89 From $94

Nov 3, 2026, 2:41 PM UTC · Primary ticker $BMRN

Wedbush Securities has lowered its price target for BioMarin Pharmaceutical to $89 from $94, while maintaining an Outperform rating. This adjustment follows the company's Q3 2026 earnings release and updated financial expectations, suggesting a slightly less optimistic outlook from the analyst.

Wedbush Securities reduced its price target for BioMarin Pharmaceutical (BMRN) from $94 to $89. This change occurred after BioMarin's Q3 2026 earnings release, which included updated financial expectations for the remainder of the year. While the Outperform rating was maintained, the lower price target indicates that Wedbush sees slightly less upside potential for the stock in the near term. This could lead to some negative sentiment among investors, as analyst price target adjustments often influence trading decisions. For traders, this presents a short-term headwind, though the maintained Outperform rating suggests long-term confidence in the company's fundamentals.

$BMRN negative Price target reduction
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.